Volume 5 Issue 3, Sep 2020

ISSN: 2095-9907 

EISSN: 2059-23635 

2023 impact factor 40.8 

 (Clarivate Analytics, 2024)
Volume 5 Issue 3, Sep 2020:
Research Highlight
The first human trial of CRISPR-based cell therapy clears safety concerns as new treatment for late-stage lung cancer
Shenghui He  ORCID: orcid.org/0000-0001-8842-7137